ReviewDrugs2013
Shingles (herpes zoster) vaccine (zostavax(®)): a review of its use in the prevention of herpes zoster and postherpetic neuralgia in adults aged ≥50 years.
Review in Drugs, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Evaluation of the economic burden of Herpes Zoster (HZ) infection.Human vaccines & immunotherapeutics · 2015Pooled it
- The Hypothesis of Myelinodegeneration as an Initial Risk of Neuropathic Pain.Neuroscience bulletin · 2026Review
- Venlafaxine for the Prevention of Postherpetic Neuralgia in Patients with Acute Herpes Zoster: Protocol for a Randomized Controlled Trial.Journal of pain research · 2026Article
- KA101 outperforms other clinical adjuvants in inducing balanced Th1/Th2 immunity and robust B cell responses to varicella-zoster virus glycoprotein E.Frontiers in immunology · 2026Article
- Subcutaneous acupuncture improves acyclovir-ineffective cephalofacial herpes zoster: A case report.Medicine · 2025Article
- Article
- Turning the Tide against Herpes Zoster in Rheumatoid Arthritis Patients Treated with JAK Inhibitors.Journal of clinical medicine · 2024Article
- Community-Based Cross-Sectional Assessment Survey On Herpes Zoster Vaccination Practices.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2024Article
- Article
- Insights into the pathogenesis of varicella viruses.Current clinical microbiology reports · 2019Article
- Robust gene expression changes in the ganglia following subclinical reactivation in rhesus macaques infected with simian varicella virus.Journal of neurovirology · 2017Article
- Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific.BMC infectious diseases · 2017Review
- Herpes zoster and the search for an effective vaccine.Clinical and experimental immunology · 2017Review
- Ocular herpes: the pathophysiology, management and treatment of herpetic eye diseases.Virologica Sinica · 2014Review
- Adverse reactions to biologic agents and their medical management.Nature reviews. Rheumatology · 2014Review
- Vaccination against and treatment of acute herpes zoster for prevention of post-herpetic neuralgia.Current pain and headache reports · 2013Review
- Safety and effectiveness of the herpes zoster vaccine to prevent postherpetic neuralgia: 2014 Update and consensus statement from the Canadian Pain Society.Pain research & managementArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The live, attenuated shingles (herpes zoster) vaccine Zostavax(®) is approved in the EU for use in the prevention of herpes zoster and postherpetic neuralgia in adults aged ≥50 years. In adults aged ≥60 years, zoster vaccine reduced the burden of illness associated with herpes zoster, with reductions in the incidence of postherpetic neuralgia and herpes zoster, according to the results of the Shingles Prevention Study. Results of subsequent Short- and Long-Term Persistence Substudies indicate that the efficacy of zoster vaccine is maintained in the longer term, albeit with a gradual decline over time. In the Zostavax Efficacy and Safety Trial, zoster vaccine reduced the incidence of herpes zoster in adults aged 50-59 years. Findings of these studies are supported by the results of large, retrospective, cohort studies. Zoster vaccine was generally well tolerated, with injection-site adverse events being the most commonly reported adverse events. In conclusion, zoster vaccine provides an important opportunity to reduce the burden of illness associated with herpes zoster by reducing the incidence of herpes zoster and postherpetic neuralgia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.